Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities

被引：11

作者：

Rubinstein, Jeremy D. ^{[1
,2
]}

Nelson, Adam S. ^{[1
,3
]}

Krupski, Christa ^{[1
,3
]}

O'Brien, William ^{[4
,5
]}

Taylor, J. Michael ^{[1
,6
]}

Badgett, Tom C. ^{[7
]}

Huang, Michael ^{[8
]}

Davies, Stella M. ^{[1
,3
]}

Phillips, Christine L. ^{[1
,2
]}

机构：

[1] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA

[2] Cincinnati Childrens Hosp Med Ctr, Div Oncol, Canc & Blood Dis Inst, 3333 Burnet Ave,MLC 7015, Cincinnati, OH 45229 USA

[3] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA

[4] Univ Cincinnati, Coll Med, Dept Radiol, Cincinnati, OH USA

[5] Cincinnati Childrens Hosp Med Ctr, Dept Radiol & Med Imaging, Cincinnati, OH 45229 USA

[6] Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati, OH 45229 USA

[7] Univ Kentucky, Dept Pediat, Coll Med, Lexington, KY USA

[8] Univ Louisville, Sch Med, Pediat Canc & Blood Disorders, Louisville, KY 40292 USA

来源：

PEDIATRIC BLOOD & CANCER | 2020年 / 67卷 / 04期

关键词：

CAR-T; cellular therapy; neurotoxicity; pre-B ALL; CYTOKINE RELEASE SYNDROME; NEUROTOXICITY; BIOMARKERS; CHILDREN;

D O I：

10.1002/pbc.28199

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chimeric antigen receptor T cells (CAR-T) are an effective and potentially durable treatment for refractory and multiply relapsed B-cell acute lymphoblastic leukemia. Neurotoxicity is frequent after CAR-T cell therapy. Mechanisms driving neurotoxicity are incompletely understood, and symptoms can range from transient and mild to severe and life-threatening. Providers have exercised caution in providing CAR-T to patients with neurological comorbidities or extramedullary disease. Here, we report three patients with prior significant neurologic morbidity who safely tolerated CAR-T cell infusion after bridging therapy with conventional chemotherapy.

引用

页数：5

共 50 条

[31] NURSING IMPLICATIONS OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
Hansen, Brenna
Cotton, Stephanie
Brudno, Jennifer
Kochenderfer, James
ONCOLOGY NURSING FORUM, 2017, 44 (02)
[32] Recent advances in chimeric antigen receptor T-cell therapy
Chihara, Dai
ANNALS OF ONCOLOGY, 2022, 33 : S431 - S431
[33] Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors
Wala, Jeremiah A.
Hanna, Glenn J.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (06) : 1149 - 1168
[34] Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy
Chodnicki, Kevin D.
Prasad, Sashank
SEMINARS IN OPHTHALMOLOGY, 2021, 36 (04) : 329 - 334
[35] Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy
Gill, Jashan
CURRENT CARDIOLOGY REVIEWS, 2023, 19 (01) : 54 - 54
[36] Utilization of Chimeric Antigen Receptor T-cell Therapy in Adults
Dudley, Channing Vail
Baer, Brittney
Simons, Rhea Micci
SEMINARS IN ONCOLOGY NURSING, 2019, 35 (05)
[37] Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist
Maus, Marcela V.
Levine, Bruce L.
ONCOLOGIST, 2016, 21 (05): : 608 - 617
[38] Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma
Atrash, Shebli
Ali, Syed Abbas
Usmani, Saad Z.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (01): : 21 - 34
[39] OPTIMIZATION OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR MEDULLOBLASTOMA
Nellan, Anandani
Rota, Christopher
Warren, Katherine
Lee, Daniel
NEURO-ONCOLOGY, 2016, 18 : 106 - 106
[40] Chimeric antigen receptor T-cell therapy for multiple myeloma
Naoki Hosen
International Journal of Hematology, 2020, 111 : 530 - 534

← 1 2 3 4 5 →